High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease
- PMID: 11173875
- DOI: 10.1159/000051236
High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease
Abstract
In order to study progressive dementia in Alzheimer's disease (AD) patients, we analyzed the gene expression of apolipoprotein E (apoE). ApoE mRNA level in the brains of patients with AD was determined by the reverse transcriptase-polymerase chain reaction (RT-PCR) method. ApoE genotype and the promoter polymorphisms (-491A/T, Th1/E47cs) were determined by the PCR restriction fragment length polymorphism method. The apoE mRNA level was significantly higher in the AD group than the control group (p < 0.05). ApoE mRNA in the AD group with apoE epsilon 4 was also significantly higher than that in the control group with apoE epsilon 4 (p < 0.05). Our result did not indicate the possibility that the promoter polymorphisms modulate the apoE mRNA level. The higher level of apoE mRNA in AD with apoE epsilon4 may play an important role in the development of AD.
Copyright 2001 S. Karger AG, Basel
Similar articles
-
Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):928-33. doi: 10.1136/jnnp.2004.048983. J Neurol Neurosurg Psychiatry. 2005. PMID: 15965197 Free PMC article.
-
Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene.J Mol Neurosci. 2004;23(3):225-33. doi: 10.1385/JMN:23:3:225. J Mol Neurosci. 2004. PMID: 15181251 Review.
-
Promoter polymorphism (-491A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals.J Neurol. 1999 Sep;246(9):821-4. doi: 10.1007/s004150050461. J Neurol. 1999. PMID: 10525981 Clinical Trial.
-
Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease.Hum Mol Genet. 1998 Sep;7(9):1511-6. doi: 10.1093/hmg/7.9.1511. Hum Mol Genet. 1998. PMID: 9700208
-
[Causative genes in Alzheimer's disease].Nihon Ronen Igakkai Zasshi. 2001 Mar;38(2):117-20. doi: 10.3143/geriatrics.38.117. Nihon Ronen Igakkai Zasshi. 2001. PMID: 11305015 Review. Japanese.
Cited by
-
Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):928-33. doi: 10.1136/jnnp.2004.048983. J Neurol Neurosurg Psychiatry. 2005. PMID: 15965197 Free PMC article.
-
Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene.J Mol Neurosci. 2004;23(3):225-33. doi: 10.1385/JMN:23:3:225. J Mol Neurosci. 2004. PMID: 15181251 Review.
-
Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives.IBRO Neurosci Rep. 2023 Nov 30;16:8-42. doi: 10.1016/j.ibneur.2023.11.003. eCollection 2024 Jun. IBRO Neurosci Rep. 2023. PMID: 38169888 Free PMC article. Review.
-
Pathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellum.PLoS One. 2013;8(3):e59166. doi: 10.1371/journal.pone.0059166. Epub 2013 Mar 13. PLoS One. 2013. PMID: 23516609 Free PMC article.
-
Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease.Gene. 2012 Jun 10;501(1):63-78. doi: 10.1016/j.gene.2012.01.049. Epub 2012 Jan 30. Gene. 2012. PMID: 22310385 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous